MedTrace Logo

Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance

NCT03880058 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-04-18

Study results available
· View outcomes & findings →

Summary

Multicenter, double-blind study comparing SLI-F06 to vehicle formulation buffer for the improvement in scar appearance and wound strength in routine surgical excisions, as well as post-operative abdominoplasty scar appearance.

Conditions

  • Scars

Interventions

DRUG

SLI-F06

Active treatment

DRUG

Formulation buffer

Placebo treatment

Sponsors & Collaborators

  • ethica Clinical Research Inc.

    collaborator INDUSTRY

  • Scarless Laboratories, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert D. Galiano, MD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-03
Primary Completion
2021-05-18
Completion
2021-05-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03880058 on ClinicalTrials.gov